<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04954183</url>
  </required_header>
  <id_info>
    <org_study_id>21-000676</org_study_id>
    <nct_id>NCT04954183</nct_id>
  </id_info>
  <brief_title>Development of an EEG Diagnostic for Alzheimer's Disease</brief_title>
  <official_title>Development of an EEG Diagnostic for Alzheimer's Disease: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SPARK Neuro Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to collect and compare electroencephalogram data from all&#xD;
      stages of Alzheimer's disease from preclinical through severe dementia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Obtain electroencephalogram (EEG) data</measure>
    <time_frame>1 year</time_frame>
    <description>Number of EEG data on individuals at all stages of Alzheimer's disease from preclinical through severe dementia.</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia With Lewy Bodies</condition>
  <condition>Normal Control APOE e4 Carriers and Noncarriers</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with moderate to severe dementia, mild stage dementia, amnestic MCI,&#xD;
        presymptomatic APOE e4 carriers, and age, sex, and education matched APOE e4 noncarriers&#xD;
        will be recruited at Mayo Clinic Arizona to obtain EEG data.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  5 individuals with moderate to severe dementia, 5 with mild stage dementia, 5 with&#xD;
             amnestic MCI, 5 presymptomatic APOE e4 carriers, and 5 age, sex, and education matched&#xD;
             APOE e4 noncarriers. Additionally we will include a group of 5 patients with mild to&#xD;
             moderate stage dementia with Lewy bodies (DLB), the second most common degenerative&#xD;
             dementia, to explore differences from clinically typical Alzheimer's disease patients&#xD;
             given the known clinical differences in EEG dysrhythmic severity between them (total&#xD;
             of 30).&#xD;
&#xD;
          -  Unimpaired APOE e4/4 homozygotes age 65-75 and APOE e3/4 heterozygotes age 75-85 for&#xD;
             the preclinical AD subset and age, sex, and education matched APOE e4 noncarriers for&#xD;
             the unaffected controls.&#xD;
&#xD;
          -  Biomarker confirmation for preclinical diagnosis will be utilized to the extent&#xD;
             possible (a subset of 130 members of our cohort have undergone amyloid-PET resulting&#xD;
             in approximately 45 who are amyloid positive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous stroke.&#xD;
&#xD;
          -  Severe head injury.&#xD;
&#xD;
          -  Craniotomy.&#xD;
&#xD;
          -  Any other potentially confounding neurologic illness (typically anything that causes&#xD;
             structural brain damage).&#xD;
&#xD;
          -  Psychoactive medication use will not be an absolute exclusionary criterion in patients&#xD;
             with moderate to severe dementia but patients who are relatively drug-free will be&#xD;
             prioritized to the extent they are available within the study period.&#xD;
&#xD;
          -  Psychoactive drug use will be exclusionary in the prospectively obtained clinical&#xD;
             patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Caselli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Richard J. Caselli</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

